Diagnostic role of survivin in urinary bladder cancer

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 81-85

  Srivastava, Anupam Kumar ^a   Singh, Pankaj Kumar ^a   Srivastava, Kirti ^a   Singh, Dhramveer ^a   Dalela, Divakar ^a   Rath, Srikanta Kumar ^b   Goel, Madhu Mati ^a   Bhatt, Madan Lal Brahma ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Diagnosis; Survivin; Urinary biomarker; Urinary bladder cancer

Indexed keywords

EID: 84877134137     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.81     Document Type: Article

References (32)

1. Agarwal PK, Black PC, Kamat AM (2008). Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol, 26, 39-44.
2. Ambrosini G, Adida C, Altieri D (1997). A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med, 3, 917-21.
3. Altieri DC (2003). Survivin in apoptosis control and cell cycle regulation in cancer. Progress in Cell Cycle Res, 5, 447-52.
4. Azuhata T, Scott D, Takamizawa S, et al (2001). The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg, 36, 1785-91.
5. Boman H, Hedelin H, Holmang S, (2002). Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol, 16, 780-3.
6. Brown FM (2000). Urine cytology. It is still the gold standard for screening? Urol Clin North Am, 27, 25-37.
7. Davido HT, Getzenberg RH (2002). Utilization of a urine-based assay for BLCA-4 in the detection of bladder cancer. J Clinical Ligand Assay, 25, 83-6.
8. Epstein JI, Amin MB, Reuter VR, et al (1998). The world health organization/international society of urological pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. bladder consensus conference committee. Am J Surg Pathol, 22, 1435-48.
9. rd edition, World Health Organization, Geneva.
10. Fuessel S, Kueppers B, Ning S, et al (2004). Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells. J Urol, 171, 2471-6.
11. Grossfeld GD, Carroll PR (1998). Evaluation of asymptomatic microscopic hematuria. Urol Clin N Am, 25, 661-76.
12. Goebell PJ, Groshen SL, Schmitz-Drager BJ (2008). Guidelines for development of diagnostic markers in bladder cancer. World J Urol, 26, 5-11.
13. Giodini A, Kallio MJ, Wall NR, et al (2002). Regulation of microtubule stability and mitotic progression by survivin. Cancer Res, 62, 2462-7.
14. Ikeguchi M, Kaibara N (2002). Survivin, messenger RNA expression is a good prognostic biomarker for oesophageal carcinoma. Bri J Cancer, 87, 883-7.
15. Kausch I, Bohle A (2001). Bladder cancer. II. Molecular aspects and diagnosis. Eur Urol, 39, 498-506.
16. Konety BR, Getzenberg RH (2001). Urine based markers of urological malignancy. J Urol, 165, 600-11.
17. Lokeshwar VB, Soloway MS (2001). Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol, 165, 1067-77.
18. Ohsawa I, Nishimura T, kondo Y, et al (2004). Detection of urine survivin in 40 patients with bladder cancer. J Nippon Med Sch, 71, 379-83.
19. Rodel F, Hoffmann J, Grabenbauer GG, et al (2002). High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol, 178, 426-35.
20. Ryan BM, Konecny GE, Kahlert S, et al (2006). Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol, 17, 597-04.
21. Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011. the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin, 61, 212-36.
22. Swana HS, Grossman D, Anthony JN, et al (1999). Tumor content of the antiapoptotic molecule SURVIVIN and recurrence of bladder cancer. N Engl J Med, 34, 1452-53.
23. Smith SD, Wheeler MA, Plescia J, et al (2001). Urine detection of survivin and diagnosis of bladder cancer. JAMA, 285, 324-8.
24. Shariat SF, Casella R, Khoddami SM, et al (2004). Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. Urol, 171, 626-30.
25. th edition. John Wiley & Sons, New York.
26. SUN Yi, HE Da-Lin, MA Qiang, et al (2006). Comparison of seven screening methods in the diagnosis of bladder cancer. Chinese Med J, 119, 1763-71.
27. Sharp JD, Hausladen DA, Maher MG, et al (2002). Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci, 7, 36-41.
28. Uren AG, Wong L, Pakusch M, et al (2000). Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol, 10, 1319-28.
29. Viv Bewick, Liz Cheek, Jonathan Ball (2004). Statistics review 13: Receiver operating characteristic curves. Critical Care, 8, 508-12.
30. Wang T, Qian X, Liu B (2007). Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol, 13, 2784-90.
31. Weikert S, Christoph F, Schrader M, et al (2005) Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis. Int J Cancer, 116, 100-04.
32. Walsh PC, Retik Ab, Vaughn ED, et al (1997) Campbell's Urology. Philadelphia, WB Saunders, Co., 2354-57.